Skip to content

Legal news

Supreme Court Rules on Biosimilar Products

Posted Jun 16, 2017

The Supreme Court ruled  that makers of copycat versions of biologic drugs, known as “biosimilars” can give 180-day notice of sales before their products win approval by the Food and Drug Administration.  The ruling should speed up access to lower-cost drugs to the public, and possibly mean billions of dollars in revenue loss for the makers of the original drug versions.  Read articles in Reuters and the Washington Post.